The sleep effects of lurasidone: a placebo-controlled cross-over study using a 4-h phase-advance model of transient insomnia.
Lurasidone, an atypical antipsychotic, is a potent 5-HT7 antagonist and D2 , 5-HT2A antagonist, and 5-HT1A partial agonist. As such, lurasidone would be expected to modulate sleep and circadian function but there have been no human studies of the sleep effects of a 5-HT7 antagonist. The purpose of this study was to assess effects of lurasidone on sleep.



This was a cross-over, polysomnographic study involving 54 healthy volunteers who underwent two treatment periods (order randomized) each consisting of two nights in the laboratory: Night 1-lights out at usual bedtime; Night 2-4-h advance of sleep phase and randomization to either lurasidone 40 mg or placebo. The next morning impairment testing was carried out.



Lurasidone significantly (p < 0.05) increased total sleep time by an average of 28.4 min versus placebo, decreased wake time after sleep onset and wake time after the final awakening, and increased sleep efficiency. No other effects were found.



Lurasidone had a sleep maintenance effect without effects on sleep onset, rapid eye movement, or slow-wave sleep. Lurasidone is likely to be beneficial to patients with disturbed sleep, particularly those with sleep maintenance problems. Copyright © 2016 John Wiley & Sons, Ltd.
Duke University School of Medicine, Durham, North Carolina, USA.
Andrew D
AD
Krystal
Clinilabs and the Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Gary
G
Zammit
D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000069056:Lurasidone Hydrochloride / Q000494:pharmacology*; D008297:Male; D017286:Polysomnography; D011985:Receptors, Serotonin / Q000187:drug effects; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D012894:Sleep Stages / Q000187:drug effects*
D014150:Antipsychotic Agents; D011985:Receptors, Serotonin; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists; C104425:serotonin 7 receptor; D000069056:Lurasidone Hydrochloride
5HT-7; lurasidone; phase advance; sleep